TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02312492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oleic Diet
Description: The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palmitic Diet
Description: The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stearic Diet
Description: The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
Study: NCT02294240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy dense biscuits
Description: Energy dense biscuits will be provided

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Flour, oil, iron & Folic acid
Description: Wheat flour, oil, iron and folic acid will be provided
Study: NCT01897636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle injection of DCs vaccinations
Study: NCT00546052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+) hydrochlorothiazide
Description: All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
Study: NCT00544609

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiotherapy
Description: 3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
Study: NCT02305862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Description: drug intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: drug intervention
Study: NCT04589104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth
Study: NCT02435355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based counselling
Description: The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
Study: NCT04103801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
Study: NCT04348409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide Tablets
Description: Patients will receive nitazoxanide 600 mg BID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo BID for 7 days
Study: NCT05683444

Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide infusion
Description: Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide infusion
Description: Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline infusion
Description: Saline Infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Saline infusion
Description: Saline Infusion
Study: NCT00398463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion will be administered for 14-24 hours
Study: NCT03837080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
Study: NCT00004001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study: NCT03285997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A
Description: A single 0.5mL dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Pre-filled syringe inj.
Description: A single 0.25mL dose intramuscular injection
Study: NCT00862264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Description: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Description: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Study: NCT01625754

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
Study: NCT01060358

Intervention type: PROCEDURE
Intervention: method (non-surgical) to measure neuromuscular neutral zones
Study: NCT02586792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/H7N9 virus vaccine
Description: Monovalent influenza A/H7N9 virus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/H7N9 virus vaccine
Description: Monovalent influenza A/H7N9 virus vaccine.
Study: NCT05033496

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function test
Description: Thyroid function test
Study: NCT04693962

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasmatic Fibroblast Growth Factor-23 by means of ELISA
Description: Plasma levels of FGF-23 will be measured by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasmatic Fibroblast Growth Factor-23 by means of ELISA
Description: Plasma levels of FGF-23 will be measured by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasmatic Fibroblast Growth Factor-23 by means of ELISA
Description: Plasma levels of FGF-23 will be measured by ELISA
Study: NCT01877083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Starting dose of 24 mg orally, once per day
Study: NCT02488122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Impact Exercise
Description: In these workouts, both feet leave the ground at the same time.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low Impact Exercise
Description: A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
Study: NCT04320407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osia 2 System
Description: The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
Study: NCT01302808

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Romidepsin (8 mg/m^2)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Romidepsin (10 mg/m^2)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis
Study: NCT05122234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of secretome - mesenchymal stem cell
Description: Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment of Covid-19
Description: Standard treatment of Covid-19 based on national protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment of Covid-19
Description: Standard treatment of Covid-19 based on national protocol.
Study: NCT02613728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Recovery Plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enhanced Care
Study: NCT02161679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-132 infusion is administered to participants in one arm for the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMMU-132 infusion is administered to participants in one arm for the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-132 plus Carboplatin infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMMU-132 plus Carboplatin infusion
Study: NCT03632421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT00037609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 taken by mouth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exisulind
Description: 125 mg taken by mouth twice daily.
Study: NCT06309459

Intervention type: DIAGNOSTIC_TEST
Intervention: Carbonic anhydrase staining levels
Description: CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).

Intervention type: DIAGNOSTIC_TEST
Intervention: Carbonic anhydrase staining levels
Description: CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).
Study: NCT02085603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01736579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Study: NCT01826552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osiro Hybrid Drug-Eluting Stent
Description: Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity
Description: Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
Study: NCT01908101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03797625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60mg/m2，D1，8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: 60mg/m2，D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 15mg/d，d1-d7 civ
Study: NCT01394939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV every 2 weeks.
Study: NCT00107237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788
Description: AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788
Description: AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
Study: NCT00193765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective neck dissection in early oral cancer
Description: Elective neck dissection in early node negative oral cancers at the time of primary surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Neck Dissection
Description: There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
Study: NCT01573715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIMBEX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIMBEX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIMBEX

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WITHOUT NIMBEX

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WITHOUT NIMBEX
Study: NCT00959816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
Study: NCT04495738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Toddler Drink
Description: 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Toddler Drink
Description: 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age

Intervention type: OTHER
Group type: OTHER
Intervention: Supplemental Formula for HM Group
Description: Ad libitum formula given up to 12 months of age if HM is supplemented

Intervention type: OTHER
Group type: OTHER
Intervention: Toddler Drink for HM group
Description: 16 fl oz per day if weaned from HM feedings
Study: NCT03278132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
Study: NCT04509310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Bodysuits
Description: The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
Study: NCT00294307

Intervention type: BEHAVIORAL
Intervention: Augmented Standard Care (ASC)
Description: Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners \[low intensity\];

Intervention type: BEHAVIORAL
Intervention: Resource Nurse Care (RNC)
Description: Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home \[medium intensity\];.

Intervention type: BEHAVIORAL
Intervention: Advanced Practice Nurse Care (APNC)
Description: Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers \[high intensity\].
Study: NCT03741998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal airway
Description: THRIVE with a regular nasopharyngeal airway.